JP2021524264A5 - - Google Patents

Info

Publication number
JP2021524264A5
JP2021524264A5 JP2021500150A JP2021500150A JP2021524264A5 JP 2021524264 A5 JP2021524264 A5 JP 2021524264A5 JP 2021500150 A JP2021500150 A JP 2021500150A JP 2021500150 A JP2021500150 A JP 2021500150A JP 2021524264 A5 JP2021524264 A5 JP 2021524264A5
Authority
JP
Japan
Prior art keywords
domain
modified immune
ccor
antigen
immune cell
Prior art date
Application number
JP2021500150A
Other languages
English (en)
Japanese (ja)
Other versions
JP7447388B2 (ja
JPWO2020011247A5 (https=
JP2021524264A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/095738 external-priority patent/WO2020011247A1/en
Publication of JP2021524264A publication Critical patent/JP2021524264A/ja
Publication of JP2021524264A5 publication Critical patent/JP2021524264A5/ja
Publication of JPWO2020011247A5 publication Critical patent/JPWO2020011247A5/ja
Application granted granted Critical
Publication of JP7447388B2 publication Critical patent/JP7447388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021500150A 2018-07-13 2019-07-12 感染性疾患の治療のための共受容体システム Active JP7447388B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/095650 2018-07-13
CN2018095650 2018-07-13
CN2019087259 2019-05-16
CNPCT/CN2019/087259 2019-05-16
PCT/CN2019/095738 WO2020011247A1 (en) 2018-07-13 2019-07-12 Co-receptor systems for treating infectious diseases

Publications (4)

Publication Number Publication Date
JP2021524264A JP2021524264A (ja) 2021-09-13
JP2021524264A5 true JP2021524264A5 (https=) 2022-07-14
JPWO2020011247A5 JPWO2020011247A5 (https=) 2022-07-14
JP7447388B2 JP7447388B2 (ja) 2024-03-12

Family

ID=69142117

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021500150A Active JP7447388B2 (ja) 2018-07-13 2019-07-12 感染性疾患の治療のための共受容体システム

Country Status (9)

Country Link
US (1) US20210275589A1 (https=)
EP (1) EP3820888A4 (https=)
JP (1) JP7447388B2 (https=)
KR (1) KR20210031898A (https=)
CN (1) CN112334479A (https=)
AU (1) AU2019302603A1 (https=)
SG (1) SG11202012339WA (https=)
TW (1) TWI841576B (https=)
WO (1) WO2020011247A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3402483T3 (da) 2016-01-15 2024-01-02 American Gene Tech Int Inc Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
DK3426777T3 (da) 2016-03-09 2022-04-25 American Gene Tech Int Inc Kombinationsvektorer og fremgangsmåder til behandling af cancer
IL284348B2 (en) 2016-07-08 2025-06-01 American Gene Tech Int Inc Hiv pre-immunization and immunotherapy
CA3064442A1 (en) 2017-06-16 2018-12-20 American Gene Technologies International Inc. Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells
US11352646B2 (en) 2018-11-05 2022-06-07 American Gene Technologies International Inc. Vector system for expressing regulatory RNA
CN113840912A (zh) * 2019-05-16 2021-12-24 南京传奇生物科技有限公司 包含识别分子的工程化免疫细胞
JP2023516685A (ja) * 2020-03-03 2023-04-20 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド Hivを処置するためのリンパ球における外因性因子のオンデマンド発現
WO2021180832A1 (en) 2020-03-12 2021-09-16 Universiteit Gent Hybrid car and hybrid tcr cells to treat infectious diseases
US12497623B2 (en) * 2020-05-04 2025-12-16 The Trustees Of The University Of Pennsylvania Non-signaling HIV fusion inhibitors and methods of use thereof
CN116848131A (zh) * 2021-02-09 2023-10-03 南京传奇生物科技有限公司 工程化细胞及其用途
WO2025011508A1 (zh) * 2023-07-07 2025-01-16 深圳先进技术研究院 降低肿瘤内中性粒细胞水平的抗肿瘤细菌
CN120329439A (zh) * 2024-01-18 2025-07-18 中国人民解放军军事科学院军事医学研究院 一种单克隆抗体及其应用
CN121015699B (zh) * 2025-08-21 2026-04-10 广州淳泰生物医药科技有限公司 一种nkt细胞制剂及其制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5866755A (en) 1993-06-14 1999-02-02 Basf Aktiengellschaft Animals transgenic for a tetracycline-regulated transcriptional inhibitor
JPH09500526A (ja) 1993-06-14 1997-01-21 ベーアーエスエフ アクツィエンゲゼルシャフト テトラサイクリン反応性プロモーターによる真核細胞の遺伝子発現の厳密な制御
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
CA2219121A1 (en) 1995-05-26 1996-11-28 Zeneca Limited A gene switch comprising an ecdysone receptor
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
AU734051B2 (en) 1996-04-05 2001-05-31 Salk Institute For Biological Studies, The Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
CA2510003A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651174A1 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
JP2009536527A (ja) 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
KR101722261B1 (ko) 2006-10-02 2017-04-03 메다렉스, 엘.엘.시. Cxcr4에 결합하는 인간 항체 및 이의 용도
TWI570135B (zh) 2007-04-27 2017-02-11 建南德克公司 高效、穩定且非免疫抑制之抗-cd4抗體
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
JP6850528B2 (ja) * 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2014055657A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Use of a trans-signaling approach in chimeric antigen receptors
ES3063961T3 (en) * 2014-02-14 2026-04-21 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
ES2791248T3 (es) * 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
WO2016033331A1 (en) * 2014-08-28 2016-03-03 Bioatla, Llc Conditionally active chimeric antigen receptors for modified t-cells
BR112017013176A2 (en) 2014-12-19 2018-05-15 Dana-Farber Cancer Institute Inc. chimeric antigen receptors and methods for using them
KR102376244B1 (ko) * 2014-12-24 2022-03-21 오토러스 리미티드 세포
CA3197849A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
CN107708741A (zh) * 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法
EP3320087A4 (en) * 2015-07-08 2019-01-23 The Johns Hopkins University BONE MARROW FILTRATION LYMPHOCYTES (MILS) AS A T-CELL SOURCE FOR CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPY
HRP20240997T1 (hr) 2015-08-04 2024-10-25 Xyphos Biosciences Inc. Varijabilni fragmenti antitijela koji se mogu umetnuti i modificirane α1-α2 domene nkg2d liganada, kao i neprirodni nkg2d ligandi koji se vežu za neprirodne nkg2d receptore
WO2017027291A1 (en) * 2015-08-07 2017-02-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Bispecific car t-cells for solid tumor targeting
WO2017053556A1 (en) * 2015-09-22 2017-03-30 The Trustees Of The University Of Pennsylvania Method of redirecting t cells to treat hiv infection
US11052111B2 (en) * 2015-12-08 2021-07-06 Chimera Bioengineering, Inc. Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
CN107793481A (zh) * 2016-08-31 2018-03-13 南京传奇生物科技有限公司 一种靶向人cd123的嵌合受体配体及其应用
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN107619820A (zh) * 2017-09-07 2018-01-23 河南大学淮河医院 Hiv病毒潜伏库双靶向性嵌合抗原受体修饰的t细胞及其制备方法和应用

Similar Documents

Publication Publication Date Title
JP2021524264A5 (https=)
JP2022113880A5 (https=)
JP2020533958A5 (https=)
JP2021500881A5 (https=)
JPWO2020011247A5 (https=)
JP2020517295A5 (https=)
JP2020114264A5 (https=)
JP2018535701A5 (https=)
US11760806B2 (en) CD-38 directed chimeric antigen receptor constructs
JP2025032091A5 (https=)
JPWO2020228824A5 (https=)
JP2022501043A5 (https=)
JP2018527014A5 (https=)
JP2017524367A5 (https=)
JPWO2020228825A5 (https=)
FI3823665T3 (fi) BCMA-spesifisiä kimeerisiä antigeenireseptoreita ja niiden käyttöjä
JP2019523301A5 (https=)
JP2018526028A5 (https=)
JP2021513857A5 (https=)
JP2021527409A5 (https=)
JPWO2020061498A5 (https=)
JPWO2020069184A5 (https=)
RU2019107136A (ru) Выделенный альтернативный внутриклеточный сигнальный домен химерного антигенного рецептора и включающий его химерный антигенный рецептор
JPWO2020165350A5 (https=)
US20240261330A1 (en) CD19-Directed Chimeric Antigen Receptor Constructs